Skip to content
DataLookout
Menu

SPARC-LINCT07785102

Single Day of Ultra-accelerated TMS With a Single Dose of NRX-101

StatusRecruiting
PhaseEarly Phase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened
    • Start date changed from estimate of Sep 1, 2026 to Oct 1, 2026
    • Site details revised
  2. Notable Eligibility criteria expanded, about 19 words
    • Secondary endpoints: details revised at 2 of 2 entries
    • Publications: details revised at 4 of 4 entries
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Change in Montgomery-Åsberg Depression Rating Scale (MADRS)
Timeframe: From day of treatment to six weeks after treatment

Secondary (2)

Hamilton Depression Rating Scale (HAM-D)
Patient Health Questionnaire 9-item (PHQ-9)

Arms and interventions

Open-label TMS + NRX-101Experimental

20 sessions of active iTBS combined with a single dose of NRX-101

Devices: TMS

Drugs: NRX-101

Sites

1 site in 1 country

  • McLean HospitalBelmont, Massachusetts, United States